News

Thursday, 8 July 2010 - 10:57

HIV incidence is the measure of how many new HIV infections there are over a period of time. Measuring changes in HIV incidence is key to evaluating the effectiveness of prevention interventions – including the provision of antiretroviral treatment (ART), which has been shown to reduce transmission – as well as for quantifying the need for future services, which is important for planning and budgeting. One of the targets of South Africa’s HIV National Strategic Plan is to reduce HIV incidence by half from 2007 to 2011

Attached is a review of the Human Sciences Research Council'...

Read more
Thursday, 8 July 2010 - 10:08

The Department of Health has given the go-ahead for patients on antiretroviral treatment (ART) to be given three months supply of medicines instead of one month. The TAC and SECTION27 welcome this decision. It will be more convenient for patients because they will have to make fewer trips to their health facility. It will also reduce patient-load on the health system, particularly on health facility pharmacies given the shortage of pharmacists in the public health system.

Joint TAC/SECTION27 statement

6 July 2010

The Department of Health has given the go-ahead for...

Read more
Tuesday, 6 July 2010 - 15:47

TAC is saddened by the loss of our long standing comrade, Vuyani Jacobs. Vuyani joined TAC after being diagnosed with HIV while working in the Eastern Cape. He later moved to Cape Town and worked as an organizer for TAC. Vuyani continued to fight for the rights of people living with HIV at Community Media Trust, where he became the Deputy Director. Vuyani was an activist, brother, colleague, mentor and friend to many of us.

 

 

TAC is saddened by the loss of our long standing comrade, Vuyani Jacobs. Vuyani joined TAC after being diagnosed with HIV while working in...

Read more
Thursday, 1 July 2010 - 20:56

On 19 May 2010, the North Gauteng High Court handed down its judgment in this case which considered a challenge by Aurobindo – a local subsidiary of a major Indian-based generics manufacturer – to its disqualification from participating in the 2008 efavirenz tender. Efavirenz is a key ARV medicine that is used by over two-thirds of people accessing ARV treatment in the public sector.

In his judgment, Justice Prinsloo came to the conclusion “that there was a lack of procedural fairness in the process”.[2] In other words, Aurobindo should not have been disqualified from participating...

Read more

Pages